The recent announcement from the Food and Drug Administration (FDA) proposing to end the use of oral phenylephrine in over-the-counter cold and allergy medications has sent shockwaves through the healthcare industry. After an extensive review of available data, the FDA has determined that oral phenylephrine does not effectively relieve nasal congestion, contradicting its common use in popular medications such as NyQuil, Benadryl, Sudafed, and Mucinex.
At Extreme Investor Network, we are closely following this development and its potential impact on drug manufacturers like Procter & Gamble, Bayer, Johnson & Johnson spinoff Kenvue, as well as retail giants CVS and Walgreens. Should the FDA’s proposed order become finalized, companies will be forced to reformulate many of their oral cold and allergy products, potentially leading to significant changes in the market.
While the removal of oral phenylephrine may prompt consumers to seek out alternative medications or nasal spray versions, it could also have a substantial financial impact on retail stores that sold 242 million bottles of drugs containing phenylephrine in 2022, generating nearly $1.8 billion in sales.
The FDA’s decision to revoke the over-the-counter designation of oral phenylephrine as “generally recognized as safe and effective” may bring about a paradigm shift in the industry, especially considering the FDA’s assertion that oral formulations of phenylephrine are ineffective at relieving congestion.
At Extreme Investor Network, we are committed to providing our readers with timely and insightful analysis of developments in the business news sector. Stay tuned for more updates on this evolving story and its implications for investors, consumers, and the healthcare industry as a whole.